You are here: Industry Insights > drug review

News List

Weekly Pharma News Review | PharmaSources.com (0919-0923) PharmaSources.com
September 26, 2022
The news reviewed this week is from September 19 to 23, covering a total of 25 pieces of information in 4 sections, i.e. drug review, R&D, and business and listing.
Weekly Pharma News Review | PharmaSources.com (0912-0916) PharmaSources.com
September 20, 2022
The news reviewed this week is from September 12 to 16, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
Weekly Pharma News Review | PharmaSources.com (0905-0909) PharmaSources.com
September 14, 2022
The news review of this week is from September 5 to 9, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
Weekly Pharma News Review | PharmaSources.com (0829-0902) PharmaSources.com
September 06, 2022
This week, the second biological drug developed by SinoCellTech - ripertamab, a new anti-CD20 monoclonal antibody, was approved for marketing, which aroused the attention of the industry. The news review of this week is from August 29 to September 2.
Weekly Pharma News Review | PharmaSources.com (0822-0826) PharmaSources.com
August 29, 2022
The EU officially released the eagerly anticipated final revision of its GMP Annex 1 for sterile drug products. The news review of this week is from August 22 to 26, covering a total of 20 pieces of information on drug review, R&D, business, and policy.
Weekly Pharma News Review | PharmaSources.com (0815-0819) PharmaSources.com
August 23, 2022
Alphamab Oncology’s JSKN003 injection became the first Chinese bispecific antibody ADC declared for clinical use. The news review of this week is from August 15 to 19, covering a total of 24 pieces of information on drug review, R&D, and business.
Weekly Pharma News Review | PharmaSources.com (0808-0812) PharmaSources.com
August 17, 2022
The FDA approved the supplementary new drug application for Bayer’s darolutamide in combination with docetaxel, which sparked widespread social attention. The news review of this week is from August 8 to 12, covering a total of 23 pieces of information.
Weekly Pharma News Review | PharmaSources.com (May. 23th - May. 29th) PharmaSources.com
May 31, 2022
This week, a steady flow of good news kept pouring into the Chinese pharmaceutical market. The local "first-in-class" Benvimod was successfully approved by FDA while Hengrui's SHR3680 tablets in treating prostate cancer had a successful Phase III clinical
Weekly Pharma News Review | PharmaSources.com （May.16th - 20th） PharmaSources.com
May 25, 2022
The first therapeutic effect data of VV116, a small-molecule oral drug for COVID-19 of Junshi Biosciences and Vigonvita, was released this week, captivating the industry.
Weekly Pharma News Review | PharmaSources.com (May.6th to May.15th) PharmaSources.com
May 18, 2022
The most encouraging news this week is that the international, multicenter, Phase III clinical trials of Hengrui's PD-1 combination therapy for liver cancer have been announced to be successful.

Previous page 1 2 3 Next page